Informations générales
  • Catégorie de maladie Maladies endocriniennes (hors cancer) , Infections et infestations (BASEC)
  • Study Phase N/A (ICTRP)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Zurich
    (BASEC)
  • Responsable de l'étude Felix Waibel felix.waibel@balgrist.ch (BASEC)
  • Source(s) de données BASEC: Importé de 15.04.2025 ICTRP: Importé de 29.08.2024
  • Date de mise à jour 15.04.2025 16:01
HumRes47236 | SNCTP000003881 | BASEC2019-00778 | NCT04081792

Duration of antibiotic administration after amputation in case of possible residual infection in diabetic foot "Duration of antibiotic administration after amputation in case of possible residual infection in diabetic foot"

  • Catégorie de maladie Maladies endocriniennes (hors cancer) , Infections et infestations (BASEC)
  • Study Phase N/A (ICTRP)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Zurich
    (BASEC)
  • Responsable de l'étude Felix Waibel felix.waibel@balgrist.ch (BASEC)
  • Source(s) de données BASEC: Importé de 15.04.2025 ICTRP: Importé de 29.08.2024
  • Date de mise à jour 15.04.2025 16:01

Résumé de l'étude

Nowadays, the duration of antibiotic therapy is based on global experience. However, antibiotics are not without complications. The infectiology of recent years focuses on shortening the duration of antibiotics to contain the pandemic of antibiotic resistance. In the field of diabetic foot infections, it is highly likely that antibiotic consumption can be reduced by half, with a corresponding reduction in costs, side effects, and length of hospital stay.

(BASEC)

Intervention étudiée

We reduce the duration of antibiotic therapy through two different prospective studies that complement each other. In a first (prospective), randomized (participating patients are assigned to different groups by random mechanism) study, we want to investigate the duration of antibiotic administration if a residual infection is present after prior amputation. For still infected soft tissues, patients receive, depending on allocation, between 1 and 4 days of oral or intravenous (into the vein) antibiotics. In case of residual infection in the bone, patients receive, depending on allocation, between 1 and 3 weeks of oral or intravenous (into the vein) antibiotics.

 

In the second study with other patients with diabetic foot infections (who were not amputated), we investigate the respective duration between 10 and 20 days of antibiotics for pure soft tissue infections in the foot, and between 3 and 6 weeks of targeted antibiotic therapy for bone infection.

 

 

In a prospective (forward-looking), randomized (participating patients are assigned to different groups by random mechanism) study, we compare infection-free status after an antibiotic therapy duration of 10 versus 20 days (for patients with pure soft tissue infection) or 3 versus 6 weeks (for patients in whom osteomyelitis (= a bone infection) is treated without removal of the bone). Only antibiotics that are approved by Swissmedic and commonly available on the Swiss market are used. The type of antibiotic depends on the (presumably) underlying bacterium of the infection.

(BASEC)

Maladie en cours d'investigation

Diabetic foot

(BASEC)

Critères de participation
Age of majority Diabetic foot disease Osteomyelitis (bone infection) (BASEC)

Critères d'exclusion
An amputation has already been performed Removal of osteosynthesis material Already in antibiotic treatment (BASEC)

Lieu de l’étude

Zurich

(BASEC)

Switzerland (ICTRP)

Sponsor

Prof. Dr.med. Ilker Uckay Universitätsklinik Balgrist

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

Felix Waibel

044 386 57 59

felix.waibel@balgrist.ch

Universitätsklinik Balgrist

(BASEC)

Informations générales

Balgrist University Hospital, Zurich, Switzerland,

+41443863705;+41 44 386 37 05

felix.waibel@balgrist.ch

(ICTRP)

Informations scientifiques

Balgrist University Hospital, Zurich, Switzerland,

+41443863705;+41 44 386 37 05

felix.waibel@balgrist.ch

(ICTRP)

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Commission cantonale de Zurich

(BASEC)

Date d'approbation du comité d'éthique

03.09.2019

(BASEC)


Identifiant de l'essai ICTRP
NCT04081792 (ICTRP)

Titre officiel (approuvé par le comité d'éthique)
“Optimization of the surgical and medical management of diabetic foot infections” (BASEC)

Titre académique
Optimization of the Surgical and Medical Management of Diabetic Foot Infections (ICTRP)

Titre public
Optimal Antibiotics for Operated Diabetic Foot Infections (ICTRP)

Maladie en cours d'investigation
Diabetic Foot Infection;Surgical Wound;Antibiotic Side Effect;Infection (ICTRP)

Intervention étudiée
Procedure: Antibiotic therapy (ICTRP)

Type d'essai
Interventional (ICTRP)

Plan de l'étude
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)

Critères d'inclusion/exclusion
Gender: All
Maximum age: 99 Years
Minimum age: 18 Years
Inclusion Criteria:

- Age = 18 years

- Diabetic foot infections or ischemia/necrosis with surgical
amputation/disarticulation level in vicinity of MRI signs of infection

- At least two months of follow-up from hospitalization

- Patient signing to participate, including acceptance of local wound care,
-off-loading and arterial re-vascularization (if clinically indicated).

Exclusion Criteria:

- At least 5 cm of distance between amputation level and infection.

- Any concomitant infection requiring more than 5 days of systemic antibiotic therapy

- Eventual osteosynthesis material not removed (ICTRP)

non disponible

Critères d'évaluation principaux et secondaires
Number of Participants with a clinical and microbiological remission of treated infection at 2 months (ICTRP)

Anatomical Amputation Level Determination by MRI;Rates of adverse events of antibiotic therapy;Duration of wound healing time;Numbers of Cost and resource reductions;Scales of Patient's satisfaction;Statistical evaluation of risk factors for failure of remission (ICTRP)

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
Ilker U?kay, PD MD;Ilker Uckay, PD MD;Ilker U?kay, PD, MD, ilker.uckay@balgrist.ch, +41443863705;+41 44 386 37 05, Balgrist University Hospital, Zurich, Switzerland, (ICTRP)

ID secondaires
DFI_Cohort (ICTRP)

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
https://clinicaltrials.gov/ct2/show/NCT04081792 (ICTRP)

Résultats de l'essai

Résumé des résultats

non disponible

Lien vers les résultats dans le registre primaire

non disponible